Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Koos will raise the AS after clinical trails are under well underway,RS would kill the company and his 200k a year salary,do not think he wants to do that.
if they won't stop diluting pps won't go up RS will be possible
do u understand english ????? if u do , u should understand my post, here is not english class, i am investing a lot of money here. by the way where is news u posted here the news will be out on tuesday last week?????
if bmsn will get fda approval, they don't need RS becouse they will get partnership or buy out by big bio company, if they do stupid RS they will loss shareholders credit, they dumped over 700 mils share since april , where is money ????? why that money did not show 10K???? last year they said they had $20mils , that $20mils + dumped 700mil share , they should have enough money now , why they need do RS and kill shareholder , scam
Lols they have to do Rs when they have fund? are u kidding? RS is only when ceo is useless and cant find a partner to help them to step to the next phase InO( no rs)like ADXS need rs to raise fund.
Well if they have to do a reverse split which seems pretty possible, they should uplist given the opportunity
Hopefully on Monday!
Your right that happened to me yesterday! I was trying to prevent them from shorting my shares but my order disappeared! Poof!! These Mofos need to be put back on the Reg Sho List!!
Most biotechs have a similar share structure like this. Needed for funding.
It will Roll over like a Tsunami .... Dont worry about The flippers.
gl
SABAI
I wasn't trying to sell just parking a GTC order so they can't be borrowed against.
I agree. Not enough strong hands.. Too many accumulated at these prices.
after 5000 for 1 RS we will see $1s ,without RS impossible go that high
It won't retest .0025. .003 is strong support and the 200 ma is very strong also. This will stay in the .003s and staircase up until news.
If it goes all as planned with BMSN , then yes I tend to agree ! So far so good ! xi
Bmsn must retest 25 before the liftoff. Tuesdays outside key reversal is your strongest indicator that the uptrend has reversed down.
I admit that I'll go all in when this retests 25
I think it will be a 1.19 by xmas!
Any thoughts on a stock price by xmas?
Great DD ! Thanks Stervc ! Bought in yesturday , see lot of potential here with BMSN ! xi
Awesome analogy! Just look at that 1 month chart! FDA Approval imminent!
From IHUB BB Heaven, stervc: What a GREAT summary !
BMSN**Why a quick FDA Orphan Drug Approval…
Regen BioPharma, a wholly-owned subsidiary of BMSN, has submitted an Investigational New Drug (IND) Application to the FDA nearly two weeks ago for approval of its HemaXellerate I™ stem cell drug to combat Aplastic Anemia. The post below explains why we should be hearing of FDA Approval for Regen BioPharma/BMSN to move forward with their clinical trials within the next 2 to 2 ½ weeks in my opinion:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84424571
First:
Make no mistake about it that 85% of all IND applications move on to begin clinical trials as can be confirmed from the link below. So I think it is very safe to expect IND FDA Approval from this first round of FDA Approvals as this was mentioned within the link below:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83323810
Second (or Next):
Next, because of HemaXellerate I™ being eligible for Orphan Drug designation, there will be around a 70% chance that the FDA will give an accelerated approval to bypass the normal lengthy FDA Approval Process of going through Phases I, II, III, & IV that usually lasts many months and years and grant BMSN this final/full FDA Approval to move forward in as little as 60 days. You will read why I say this later within this post. Below is confirmation from the FDA website that HemaXellerate I™ will be classified as an Orphan Drug because of its use to combat Aplastic Anemia:
http://www.accessdata.fda.gov/scripts/opdlisting/oopd/OOPD_Results_2.cfm?Index_Number=092695
Quote:
http://www.trainforlifeamerica.com/go/enewsletter/health-conditions?id=45
• Aplastic anemia: This is one of the most serious types of anemia. In this serious illness, the body's bone marrow cannot produce enough of certain blood cells: red, white, or platelets. In about half the cases of aplastic anemia, the cause is never known. The known causes range from a hereditary defect, exposure to radiation or toxic chemicals, or effects of certain drugs. Certain viruses and cancers can be the underlying causes as well.
• Aplastic anemia is a less common type of anemia, affecting about one in every 25,000 people per year. It usually affects those between ages 15 and 24 or those over age 60. Both sexes are equally affected.
• Aplastic anemia – If left untreated, aplastic anemia leads to rapid death.
HemaXellerate I™ is BMSN’s stem cell drug to combat Aplastic Anemia. Aplastic Anemia is eligible for Orphan Drug Status which makes HemaXellerate I™ able to get full FDA approval in as little as 60 days to bypass the lengthy Phase I, II, III, IV FDA Approval Processes because of being eligible for Orphan Drug Status. This is because HemaXellerate I™ has been confirmed to be something special enough to save the lives of people who have been diagnosed with Aplastic Anemia which could lead to rapid death. Read below to learn more about the Orphan Drug Designation:
http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm
Because of HemaXellerate I™ being eligible to obtain Orphan Drug Status, this means the following below can work towards benefiting BMSN and its shareholders:
1**60 days or Less Accelerated final/full FDA Approval.
2**Bypass lengthy Phase I, II, III, IV FDA Approval Processes.
3**The FDA has been offering incentives for developing treatments for rare diseases since 1983, when the Orphan Drug Act became law.
4**The FDA wants to double the number of orphan drug designations that their office approves in the next five to 10 years.
5**The Orphan Drug designation comes with a 50 percent tax credit on any clinical trials that need to be conducted.
6**Drug fees, which currently cost around $1.6 million for one drug application, are eliminated.
7**The company that succeeds in getting final FDA approval will be allowed exclusive drug marketing rights for seven years.
8**Major medical companies see “confirmed” future value to be 100% on board and supportive.
9**Dr. Cote says the designation brings the new drug to the attention of investors.
Below is a quote from Dr. Timothy Cote:
Quote:
"When you get orphan status designation, you go up on our website saying that the FDA has given a nod that this is promising for this rare disease," said Cote. "And then the venture capital rains down from the heavens.
The U.S. FDA established the Orphan Drug Act (ODA) in January 1983. For those wondering who is Dr. Timothy Cote, he is the doctor that is over the Office of Orphan Products Development. Read below an important article that highlights the importance of Orphan Drugs which supports BMSN in my opinion with quotes from Dr. Timothy Cote:
Quote:
http://minnesota.publicradio.org/display/web/2010/08/05/orphan-drugs
…The FDA has been offering incentives to companies that develop treatments for rare diseases since 1983, when the Orphan Drug Act became law. …
…The FDA's Dr. Timothy Cote thinks there are many more researchers and companies who could benefit from the orphan drug designation. But he says they're often overwhelmed by the regulatory process.
"We have an opacity problem at the FDA. It's a big black box. Nobody knows what they're thinking inside," said Cote. "And we're smashing that black box. We're making it transparent and we're showing people that what we're doing is reasonable, that we don't bite, and we are just as interested in getting new drugs for people with rare diseases as the sponsors are."
Rare conditions are often described as orphan diseases when there are very few treatment options, largely due to a lack of money for drug research. There are about 7,000 known orphan diseases in the U.S.
Cote, who directs the Office of Orphan Products and Development, says most of those diseases have no approved treatment. For that reason, he wants to double the number of orphan drug designations that his office approves in the next five to 10 years. …
… The designation comes with a 50 percent tax credit on any clinical trials that need to be conducted. Drug fees, which currently cost around $1.6 million for one drug application, are eliminated. And a company that succeeds in getting final FDA approval will be allowed exclusive drug marketing rights for seven years.
But more than that, Cote says the designation brings the new drug to the attention of investors.
"When you get orphan status designation, you go up on our website saying that the FDA has given a nod that this is promising for this rare disease," said Cote. "And then the venture capital rains down from the heavens. That is how it has tended to work for a lot of these companies." …
… The FDA says it will rule on all of the applications it received while in Minneapolis within 60 days. Typically, between 55 percent and 70 percent of orphan drug status applications are approved.
Video of FDA Dr. Timothy Cote - Office of Orphan Products Development:
http://www.youtube.com/watch?v=-sKFl5lAmJE
To further add, I think these posts below by other BMSN investors are very wise to consider too by jjr04001, Zer0Veritas, and T_T23 which helped me to further educate myself on the thoughts I derived above:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84669948
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84670129
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=84671685
The poster named jjr04001 is a Pharmacist. So in my opinion, jjr04001 is more qualified than me and your average investor here which lacks any medical qualifications. Much was articulately explained by jjr04001. It was articulately explained how that with HemaXellerate I™ being a treatment for Aplastic Anemia, Aplastic Anemia is a disease which can be described currently as lacking a profit motive because of how rare the disease is and because of how expensive it is to treat. It was articulately explained to look at some of the antiviral treatments for HIV/AIDS (Glaxo's Lexiva - Fosemprenavir) or Genzyme's Fabrazyme (Agalsidase beta) to see how they did not go through 8 years of clinical trials.
Most important in my opinion to note, it was articulately explained that an orphan drug, historically, has an 83% chance of approval to phase II clinical trials, as compared to 33% for non-orphan drugs. Further, Aplastic anemia, if left untreated, WILL kill in 7 months or less. Deaths from this disease are generally quick. "Orphan drug status" is the key here. These drugs are an exception to normal regulatory pre-marketing practices. Treatments for "Orphan diseases" are a guaranteed profit as the patient is a chronic patient, always requiring therapy, payers usually had no problem covering these treatments because of how rare the diseases are, and there are incentives given federally to reduce sales cost and what have you...
Then, it was articulately explained that if you go on the website for national institute of health (NIH) and type in hemaxellerate, you will find a mechanism of the treatment and to then compare this treatment to the current modes of treatment for Aplastic Anemia (Immunosuppression, bone marrow transplant, ATG/ALG, steroids) and compare the side effects/ efficacy / safety and survival rates. Based on the professional judgment of jjr04001 (PharmD.) this treatment has a lot to offer to those who suffer from this debilitating disease (often children).
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3543295/
Below is more on the benefits provided for qualifying to be an Orphan Drug:
Quote:
http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2009/02/fda-orphan-drug-designations-are-on-the-rise.html
Orphan drug designation qualifies a company for several benefits under the ODA, as amended. These benefits include a 7-year period of orphan drug exclusivity upon product approval (which generally prevents FDA from approving another firm’s version of the “same drug” for the same disease or condition for 7 years), a tax credit for certain clinical testing expenses for the orphan drug, written guidance on the non-clinical and clinical studies needed to obtain marketing approval of an orphan drug, and orphan drug grants.
Again, Federal Grants can be given to support Orphan Drugs as explained below:
http://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/default.htm
The above is why I truly believe in the post below elaborating why I feel that BMSN has potential to be trading in the $1.19 per share range and possibly sooner than what any of us think:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=83394755
v/r
Sterling
so dilution will be going on if they need money????
Have close to 2 mil shares in low 005's. believe in these products and feel 005's could be a distant memory very soon. The wait ing is tough tho.
Am enjoying the volume as we sit on the 200 Dma!!! Lets do it
APPROVED! COMING TO A NEWS OUTLET NEAR YOU.
You are 100% correct there is not supposed to be revenue for a biotech before they have an FDA approved drug. The problem here I saw in the 10k is the constant never ending debt conversions weighing on the stock price. You need that to go away...like trying to drink the ocean through a straw. Need better funding deal in place to stop the endless waves of dilution imho.
Once you read them in detail could you please share your view on them.
Thanks in advance.
could not have explained BMSNs situation better then that
explains it to a t. Thanks for that
that is one of the best analogies I ve heard thanks for that
Yea I see his card..lol I gotta look at these reports from yesterday in detail today. BMSN is about to erupt!!
90% of all start up companies biotech or not reports -O- income. Why would they have a revenue stream with no product? Once they have a marketable FDA approved product then they can attract big pharma to buy them out! I never heard of any start-up penny stock company making millions of dollars in revenue with no product! There will be a drastic change in PPS this July as FDA response is expected to come any day now that will initiate clinical trials on humans.
Click on the link below to see why biotech companies need to dilute and what operating expenses they have?
http://www.dataev.com/it-experts-blog/bid/290624/4-Reasons-Biotech-Startups-Can-t-Afford-to-Skimp-on-IT
If I had a choice between
No bmsn stock right now and
Millions of shares in the .0080's
I would take the stock and not look at it
For a month then reap my prifits.
Think of it as farming.
Stop digging up your seed
To see if it is growing every day.
The first big harvest is around the cornrr.
hi there, I'm gad to be part of the BMSN group
n i c e o n e. GO BMSN. good timing too. Biotechs are notorious for subpar financials, especially before phase I. You think this is Google? Apples and oranges, my friend.
yep. was nice try but he is invested at least. LOL
Billion Dollar drug candidate days away from starting Human clinical trials for BMSN. Nice try though
Here's only a few of these...issue shares:
On April 24, 2012 the Company issued 3,333,333 Common Shares (“Shares”) in satisfaction of $12,000 of existing convertible debt.
The Shares were offered directly through the management. No underwriters were retained to serve as placement agents. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.
On April 30, 2012 the Company issued 835,608 Common Shares (“Shares”) in satisfaction of $3,000 of existing convertible debt.
The Shares were offered directly through the management. No underwriters were retained to serve as placement agents. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.
On May 2, 2012 the Company issued 3,000,000 Common Shares (“Shares”) in satisfaction of $3,000 of existing convertible debt.
The Shares were offered directly through the management. No underwriters were retained to serve as placement agents. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.
On May 11, 2012 the Company issued 2,564,103 Common Shares (“Shares”) in satisfaction of $10,000 of existing convertible debt.
The Shares were offered directly through the management. No underwriters were retained to serve as placement agents. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.
On May 11, 2012 the Company issued 2,564,103 Common Shares (“Shares”) in satisfaction of $10,000 of existing convertible debt.
The Shares were offered directly through the management. No underwriters were retained to serve as placement agents. No commission or other consideration was paid in connection with the sale of the Shares. There was no advertisement or general solicitation made in connection with this Offer and Sale of Shares.
On May 11, 2012 the Company issued 5,769,231 Common Shares (“Shares”) in satisfaction of $22,500 of existing convertible debt
Is this going to be one of those R/S, issue, raise A/S, repeat?
Doesn't look good to me. Any positives for BMSN? Seriously, anyone have something to help me "SEE" why I should keep my shares? Don't have a lot, but still, doesn't seem like this will go again.
GL
E
P.S. - All serious questions, no bash here. Need answers. Not pumps. Thanks.
I own BMSN.....But....ooopps-iHub slow.
I own BMSN.....But....
Why is there so much interest in the company....
Material Changes in Results of Operations
Revenues were -0- for the quarter ending March 31, 2013 and -0- for the same quarter ending 2012. Net Losses were $941,488 for the three months ended March 31, 2013. Net Losses were $504,734 for the same quarter ending 2012 .The increase in Net Loss of approximately 86% is primarily attributable to increases in expenses attributable to General and Administrative Expenses and Interest Expense Attributable to Amortization of Discount offset by decreases in Interest Expense incurred which was not attributable to Amortization of Discount, and Consulting Expenses. The Company also did not recognize any losses applicable to Equity in Losses of Subsidiary during the quarter ended March 31, 2013 due to reclassification of 10,000,000 common shares of Entest Biomedical Inc owned by the Company as Available for Sale Securities as a result of Company’s ownership of Entest Biomedical Inc falling to below 20% during the three months ended June 30, 2012. The Company recognized $343,749 of losses applicable to Equity in Losses of Subsidiary during the quarter ended March 31, 2012.
Revenues were -0- for the six months ending March 31, 2013 and -0- for the same period ending 2012. Net Losses were $1,538,154 for the six months ended March 31, 2013. Net Losses were $718,407 for the same period ending 2012 . The increase in Net Loss of approximately 114% is primarily attributable to increases in expenses attributable to General and Administrative Expenses, Research and Development expenses and Interest Expense Attributable to Amortization of Discount offset by decreases in Interest Expense incurred which was not attributable to Amortization of Discount offset by losses of $48,939 and $399,082 recognized during the six months ended March 31, 2012 attributable to early extinguishment of debt and Equity in Losses of Subsidiary respectively.
etc....
seriously,
what's on the horizon that will bring a 180 to these numbers....and quickly.
anyone got an idea why I can't trade BMSN from Germany?
Already bought some shares a few weeks ago and wanted to add more yesterday. But the orders were deleted a few minutes after they appeared in the orderbook. My broker said its due to new restrictions from Nasdaq/OTC or BMSN...
GETTING ONE STEP CLOSER TO JULY EVERY DAY !!! BMSN IS ABOUT TO EXPLODE !!!!!!!!!!!!!!
BMSN Alert: MA(200) @ 0.0035 Support held..........Huge close.......MA(200) is the biggie......run to MA(100) @ 0.0054 coming..........turn that into support & penny land is on deck!..........$$$
Excellent DD Bruce! Higher lows!! With high volume!! Massive accumulation here ppl!!
Today's bombardment of PRS was not full absorbed. Wonder if people fully read reports.
Just look at o/s , it can't be the same.
BMSN IS LITTERALLY NOT WHAT IT USED TO BE!
Followers
|
914
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
158400
|
Created
|
09/05/06
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |